AI Agents for Pharmacovigilance

This page shows how pharmacovigilance AI agents plan, execute, and verify safety signal workflows with concrete tool calls and a worked example.

By Suhas Bhairav · Updated

Direct Answer

AI agents for pharmacovigilance are goal-driven software that identify safety signals, query clinical databases, assess causality, alert analysts, and learn from outcomes; they produce traceable tool usage, data provenance, audit trails, and escalation notes, with final regulatory actions reviewed by qualified pharmacovigilance staff.

Best for: Pharmacovigilance teams, safety data managers, and clinical researchers.

What AI Agents Can Do in Pharmacovigilance

  • Signal detection

    Identify potential safety signals from spontaneous reports, EHR data, and literature, using data preprocessing, statistical methods, and anomaly checks. Stop when a signal is preliminarily evaluated or escalated. The agent records data provenance and flags data quality concerns for follow-up, ensuring reproducibility across datasets.

  • Causality assessment

    Evaluate likelihood that a drug causes an adverse event by applying Bradford Hill criteria, literature evidence, and case narrative checks, then generate a causality verdict for human review. It links evidence to a structured causality narrative and captures uncertainty assessments for regulators.

  • Case enrichment

    Gather missing details, retrieve patient histories, lab results, and product batches, then assemble a complete case file for adjudication and regulatory reporting. It annotates data sources, timestamps, and access controls to support traceability and privacy compliance.

  • Regulatory reporting

    Prepare disclosures for ADR reports, safety letters, and periodic safety update reports, formatting records to regulatory schemas and routing for final human approval. It validates field mappings, version controls, and submission checkpoints to ensure accuracy and audit trails.

  • Signal prioritization

    Rank signals by urgency, novelty, and data quality, propose follow-up analyses, and queue cases for safety team review and action. It assigns priority tags, documents rationales, and sets escalation thresholds for clear decision paths.

  • Audit and logging

    Maintain an immutable action log, tool outputs, and decision prefixes to support compliance reviews and repeatability. It timestamps actions, stores tool configurations, and enables traceable rollback if data or results are questioned.

How the Agent Works

  1. Receive goal

    User defines the safety objective and constraints; it records the target regulatory schema.

  2. Plan

    Agent outlines a plan: select data sources, preprocessing steps, tests, tool calls, and escalation stop conditions.

  3. Call tools

    Agent fetches data, queries literature, runs analyses, and assembles cases; it logs tool versions and access rights for audits.

  4. Check result

    Agent validates results against thresholds, checks data quality, and decides on escalation, summary, or handoff; it verifies provenance.

  5. Finish or hand off

    Agent closes with a final report and archive or transfers the case, creates an audit package, and notifies the reviewer group.

Worked Example

Indexing a potential signal for a new adverse event in Drug Y

Illustrative scenario with sample data.

Scenario

A fictional pharmaceutical company wants to screen incoming spontaneous reports and hospital data for a potential new adverse event linked to Drug Y in the past six months.

Input

drug: Drug Y; event: suspected acute liver injury; dataSources: spontaneousReports, EHRs, literature; privacy: compliant; turnaround: 24 hours; thresholds: signal score > 0.8 triggers review; team: pharmacovigilance unit.

What the agent does

  1. Step 1: The agent calls the data retrieval tool to pull spontaneous reports and EHR notes mentioning Drug Y and liver injury, then composes a clean dataset for analysis and flags missing fields for follow-up.
  2. Step 2: It runs disproportionality signals using a statistical method, cross-checks with case narratives, and returns a ranked list of potential signals with supporting evidence and quality flags.
  3. Step 3: The agent retrieves relevant literature and regulatory guidelines from public databases, integrates findings with the signal, and documents causality considerations in a structured report.
  4. Step 4: It assembles a case file with data provenance, generates a preliminary causality assessment, and notes required human review steps and escalation criteria.

Output

Signal: potential signal Drug Y–liver injury with score 0.85; supporting data: 12 spontaneous reports, 5 EHR cases, 3 literature hits; preliminary causality: indeterminate; next actions: human review requested; file id: PKV-2026-047.

Human decision

A safety scientist must review the method, verify data quality, and confirm whether to escalate to regulatory reporting or suspend assessment pending additional data.

What You Need

  • Secure access to pharmacovigilance databases and public literature indices.
  • Defined data governance policy with data access approvals and privacy controls.
  • Clear role-based access and audit logging for data retrieval and analysis.
  • A structured incident tracking system with case IDs, timestamps, and versioned reports.

Where People Stay in Charge

  • The agent cannot approve regulatory reports; final disposition requires pharmacovigilance leadership review.
  • The agent cannot modify patient data; human verification is required before data use in decision making.
  • All data actions and conclusions must be reviewed by a licensed pharmacovigilance professional before submission.

FAQ

What is a pharmacovigilance AI agent?

A pharmacovigilance AI agent is goal-driven software that plans data gathering, applies causal and statistical methods, generates signals, and hands off to humans when needed, with tool outputs and traces for audit.

What data sources does it use?

It uses spontaneous reports, EHRs, literature, and guidelines, then integrates results into a structured case file for review, tracking provenance and data quality flags.

When does the agent stop?

The agent stops after human-approved action such as escalation or final report; it archives the case with provenance records and makes artifacts accessible for audits.

Who reviews the results?

A lead or safety physician reviews results, validates data quality, and signs off before regulatory action; they assess causality, confirm data integrity, and authorize the final report.